Clinical Trial Update: IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating an IL-12 DNA vaccine with in vivo electroporation for Merkel cell carcinoma has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• IL-12 gene and plasmid DNA vaccine with electroporation

Snippet

Sponsor: OncoSec Medical Incorporated | Conditions: Merkel Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-12-12